Provided by Tiger Trade Technology Pte. Ltd.

Eupraxia Pharmaceuticals

8.42
+0.40004.99%
Post-market: 8.420.00000.00%16:15 EDT
Volume:492.92K
Turnover:4.13M
Market Cap:556.34M
PE:-8.45
High:8.49
Open:8.14
Low:8.11
Close:8.02
52wk High:9.32
52wk Low:5.16
Shares:66.07M
Float Shares:54.50M
Volume Ratio:0.52
T/O Rate:0.90%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9967
EPS(LYR):-1.0300
ROE:-66.70%
ROA:-43.66%
PB:5.47
PE(LYR):-8.17

Loading ...

Eupraxia Pharmaceuticals (EPRX) Receives a Buy from Cantor Fitzgerald

TIPRANKS
·
Apr 01

Eupraxia Pharmaceuticals Boasts $900 Million Peak Sales Potential: Analyst

Benzinga_recent_news
·
Mar 24

Eupraxia Pharmaceuticals Initiated at Outperform by William Blair

Dow Jones
·
Mar 23

Eupraxia: Differentiated Once-Yearly EoE Therapy and Platform Expansion Support Buy Rating

TIPRANKS
·
Mar 23

Eupraxia Pharmaceuticals (EPRX) Receives a Rating Update from a Top Analyst

TIPRANKS
·
Mar 21

HD Renewable Energy Secures JPY 5.4 Billion Financing for Hokkaido BESS in Japan's First Grid-Scale Battery Green Bond

prnewswire
·
Mar 19

Eupraxia Pharmaceuticals: Durable EP-104GI Data and Upcoming Catalysts Support Buy Rating

TIPRANKS
·
Mar 19

Sector Update: Health Care Stocks Mixed Premarket Tuesday

MT Newswires Live
·
Mar 17

Eupraxia Pharmaceuticals Says Eosinophilic Esophagitis Treatment Trial Shows Over Half of Patients in Remission

MT Newswires Live
·
Mar 17

Eupraxia Pharmaceuticals Posts Strong Six-Month EoE Data for EP-104GI as RESOLVE Trial Advances

TIPRANKS
·
Mar 17

Eupraxia Pharmaceuticals’ esophagitis candidate shows symptom decrease

TIPRANKS
·
Mar 17

Eupraxia Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Mar 17

Eupraxia Pharmaceuticals Reports Six-Month Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis

GlobeNewswire
·
Mar 17

HD Renewable Energy Showcases 3GW Japan Pipeline and Power Trading Strategy at Tokyo Smart Energy Week 2026

prnewswire
·
Mar 17

Eupraxia (EPRX): Robust Cash Runway and Promising EP-104GI GI Pipeline Create Attractive Risk‑Reward and Support Buy Rating

TIPRANKS
·
Mar 17

Eupraxia Pharmaceuticals Q4 EPS $(0.37) Misses $(0.16) Estimate

Benzinga Earnings
·
Mar 13

Eupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial Results

GlobeNewswire
·
Mar 13